Labeling

These comments aim to address dietary supplement rules, regulations, guidance, or other federal policies that are inconsistent with statutory text or the Constitution, where costs exceed benefits, where regulations are outdated or unnecessary, or where regulations impose unforeseen burdens on American businesses.

CHPA supports FDA’s continued efforts to support medical device innovation by facilitating to the use of PCCPs for efficient Agency review of medical device modifications. When finalizing the Draft Guidance, CHPA strongly encourages FDA to provide further clarity regarding the content and process for PCCPs on several points.

CHPA and members of our Dietary Supplements Committee appreciate the opportunity to comment on the recently released Draft Guidance outlining FDA’s approach to food allergen labeling.

In general, members are very satisfied with the existing regulations for content on the PDP, and recommend that no additional guidance on this topic is needed.

CHPA appreciates the opportunity to provide comments on NIH ODS strategic plan 2022-2026.